- Home
- EGY vs CKPT Comparison
EGY vs CKPT Comparison
Compare EGY & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- CKPT
- Stock Information
- Founded
- EGY 1985
- CKPT 2014
- Country
- EGY United States
- CKPT United States
- Employees
- EGY N/A
- CKPT N/A
- Industry
- EGY Oil & Gas Production
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- CKPT Health Care
- Exchange
- EGY Nasdaq
- CKPT Nasdaq
- Market Cap
- EGY 340.3M
- CKPT 361.1M
- IPO Year
- EGY N/A
- CKPT 2017
- Fundamental
- Price
- EGY $3.22
- CKPT $4.26
- Analyst Decision
- EGY Strong Buy
- CKPT Buy
- Analyst Count
- EGY 1
- CKPT 3
- Target Price
- EGY $8.00
- CKPT $4.33
- AVG Volume (30 Days)
- EGY 1.1M
- CKPT 2.1M
- Earning Date
- EGY 05-08-2025
- CKPT 05-13-2025
- Dividend Yield
- EGY 7.89%
- CKPT N/A
- EPS Growth
- EGY N/A
- CKPT N/A
- EPS
- EGY 0.56
- CKPT N/A
- Revenue
- EGY $489,162,000.00
- CKPT $41,000.00
- Revenue This Year
- EGY N/A
- CKPT $102,182.93
- Revenue Next Year
- EGY $25.43
- CKPT $351.71
- P/E Ratio
- EGY $5.70
- CKPT N/A
- Revenue Growth
- EGY 3.02
- CKPT N/A
- 52 Week Low
- EGY $3.00
- CKPT $1.80
- 52 Week High
- EGY $7.43
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- EGY 39.86
- CKPT 80.26
- Support Level
- EGY $3.14
- CKPT $4.14
- Resistance Level
- EGY $3.33
- CKPT $4.20
- Average True Range (ATR)
- EGY 0.12
- CKPT 0.03
- MACD
- EGY -0.02
- CKPT -0.00
- Stochastic Oscillator
- EGY 4.05
- CKPT 85.71
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.